anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: The aim of this study was to compare the guardian-perceived 3-month cosmetic outcome for pediatric lacerations repaired with absorbable sutures, Dermabond, or Steri-Strips. Secondarily, pain and satisfaction with the procedure from both guardian and provider perspectives were compared.
METHODS: In this randomized controlled trial, we enrolled a convenience sample of children aged 0 to <18 years who presented with simple linear lacerations (≤5 cm in length, ≤0.5 cm in width, and <12 hours old) to a pediatric emergency department. Children were randomized to receive laceration repair with absorbable sutures, Dermabond, or Steri-Strips. Topical L.E.T. solution (lidocaine, epinephrine, tetracaine) was applied to wounds which were then closed by the primary team. Guardians and providers completed questionnaires regarding perceived pain and satisfaction with the procedure. Guardians were contacted 3 months after the repair and asked to email a picture of the scar with their perception of cosmesis rated on a visual analog scale from 0 to 100.
RESULTS: Fifty-five patients were enrolled, of whom 30 completed 3-month follow-up (12 suture, 7 Dermabond, 11 Steri-strips). There was no statistical evidence of an association between scar appearance and closure method based on medians and interquartile ranges for cosmetic ratings of scar: suture median 70.5 (IQR 59.8-76.8), Dermabond median 85 (IQR 73-90), Steri-strips median 67 (IQR 55-78) ( P = 0.254). Guardian satisfaction with length of stay, guardian and physician satisfaction with the procedure, and guardian and physician-perceived pain also showed no differences.
CONCLUSIONS: No differences were observed in guardian-perceived cosmesis of simple lacerations repaired with sutures, Dermabond, or Steri-Strips when evaluated 3 months after intervention. In addition, there were no differences in guardian or physician-perceived pain or satisfaction with the closure methods. The results of this study suggest that all 3 closure methods appear to be clinically equivalent, which is largely consistent with other evidence. Further study should be expanded to a larger demographic.
Accidental overdosage following administration of enoxaparin sodium injection may lead to hemorrhagic complications. Injected enoxaparin sodium injection may be largely neutralized by the slow intravenous injection of protamine sulfate (1% solution). The dose of protamine sulfate should be equal to the dose of enoxaparin sodium injected: 1 mg protamine sulfate should be administered to neutralize 1 mg enoxaparin sodium injection, if enoxaparin sodium injection was administered in the previous 8 hours. An infusion of 0.5 mg protamine per 1 mg of enoxaparin sodium may be administered if enoxaparin sodium was administered greater than 8 hours previous to the protamine administration, or if it has been determined that a second dose of protamine is required. The second infusion of 0.5 mg protamine sulfate per 1 mg of enoxaparin may be administered if the aPTT measured 2 to 4 hours after the first infusion remains prolonged.

If at least 12 hours have elapsed since the last enoxaparin sodium injection, protamine administration may not be required; however, even with higher doses of protamine, the aPTT may remain more prolonged than following administration of heparin. In all cases, the anti-Factor Xa activity is never completely neutralized (maximum about 60%). Particular care should be taken to avoid overdosage with protamine sulfate. Administration of protamine sulfate can cause severe hypotensive and anaphylactoid reactions. Because fatal reactions, often resembling anaphylaxis, have been reported with protamine sulfate, it should be given only when resuscitation techniques and treatment of anaphylactic shock are readily available. For additional information consult the labeling of protamine sulfate injection products.
<P>PROBLEM TO BE SOLVED: To provide a structure-stabilizing technique excellent in safety which can replace heretofore-known structure-stabilizing means.  <P>SOLUTION: A cream-like detergent containing a fatty acid potassium salt is caused to contain a polyoxyethylene branched fatty acid glyceryl ester as a detergent component. An isostearic acid residue is particularly preferable as the branched fatty acid residue. In a preferable form, the detergent component is a combination of the polyoxyethylene monobranched fatty acid glyceryl ester and a polyoxyethylene tribranched fatty acid glyceryl ester. In a particularly preferable form, the detergent component is a combination of the glyceryl polyoxyethylene(20)triisostearate and a glyceryl polyoxyethylene(20)monoisostearate.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Participants received standard chemotherapy regimen (FOLFIRI) consisting of 5-FU, leucovorin and irinotecan. Treatment is administered in cycles every two weeks.
The present invention provides an injectable and antibacterial bifunctional hydrogel, a preparation method therefor, and an application thereof, pertaining to biomedical materials. The bifunctional hydrogel is a hydrogel prepared by dissolving a nucleoside analog in a solvent. The structure of the nucleoside analog is as shown in formula I. The hydrogel is simple to prepare and environmentally friendly, and has a good shear thinning and self-repairing properties, good injectability, and a high gelling speed, and is convenient to use. The hydrogel also has excellent mechanical properties. Furthermore, the hydrogel has a good antibacterial effect. In addition, the hydrogel has good stability at room temperature and can be stored for a long time, and can be quickly degraded after being implanted in the human body, and has good biocompatibility. With these outstanding features, the hydrogel of the present invention is expected to be a candidate drug for local injection treatment of periodontal disease, and also has potential application prospects in minimally invasive treatment of cranio-maxillofacial bone tissue defects.
Most of pharmaceutical agents display a number of biological activities. It is obvious that testing even one compound for thousands of biological activities is not practically possible. A computer-aided prediction is therefore the method of choice in this case to select the most promising bioassays for particular compounds. Using the PASS Online software, we determined the probable anti-inflammatory action of the 12 new hybrid dithioloquinolinethiones derivatives. Chemical similarity search in the World-Wide Approved Drugs (WWAD) and DrugBank databases did not reveal close structural analogues with the anti-inflammatory action. Experimental testing of anti-inflammatory activity of the synthesized compounds in the carrageenan-induced inflammation mouse model confirmed the computational predictions. The anti-inflammatory activity of the studied compounds (2a, 3a-3k except for 3j) varied between 52.97% and 68.74%, being higher than the reference drug indomethacin (47%). The most active compounds appeared to be 3h (68.74%), 3k (66.91%) and 3b (63.74%) followed by 3e (61.50%). Thus, based on the in silico predictions a novel class of anti-inflammatory agents was discovered.
FIELD: medicine, oncology. SUBSTANCE: based on established fact of enhancement of antiblastic activity of platinum coordinating compounds in their using in combination with 1,10-phenanthroline and ascorbic acid the composition comprising of indicated substances taken in the weight ratio = (1:1:1) - (1:1:10) is determined. Composition shows the expressed enhancement of antitumor cytostatic activity indicating the regularity of potentiation effect. Invention can be used in chemotherapy of malignant tumors. EFFECT: enhanced effectiveness of composition, valuable medicinal properties. 3 tbl, 3 ex
A virulent strain of Equine Rhinopneumonitis (ERP) Virus was passed for 50 passages through the Vero Cell Line (monkey Kidney) at 26° C. At the end of this treatment, it had become attenuated so that a vaccine formed from the virus gave none of the usual ERP symptoms when horses were inoculated with the vaccine by the I. M. route, i.e., they showed none of the usual nasal and ocular discharges, no fever, no anorexia and the like. When the vaccinates were challenged with virulent virus, none of the clinical symptoms of Equine Rhinopneumonitis Virus appeared, while unvaccinated control animals, so challenged, contracted ERP within 3-4 days with all the classical symptoms. 
     The vaccination of a mare prior to breeding and again during her pregnancy will prevent abortions caused by virulent ERP virus. Other horses should be vaccinated once a year in order to prevent the Equine Rhinopneumonitis disease complex. Foals may be vaccinated any time after 1 day of age even in the face of maternal antibody. The ERP Vaccine Virus may be administered parenterally or extra-parenterally to the mucosal surfaces of the body. The I. M. route of inoculation is recommended.
The present invention relates to a method for performing a cooking process on a food product ready to be cooked on the basis of a cooking recipe information provided in a cooking recipe (10). At least one food model (30) is generated on the basis of the cooking recipe information and a database (14, 16, 20, 22, 26, 28). The cooking recipe (10) comprises at least one of the information about: —an ingredient, —a preparation step or process, —the shape of unprocessed food, and —composition, properties and condition of the food product. The database (14, 16, 20, 22, 26, 28) comprises information about ingredients and/or unprocessed food, which may be basic nutrient information of ingredients and/or unprocessed food, particularly information about content of at least one of: water, fat, carbohydrates and proteins. The database (14, 16, 20, 22, 26, 28) may also comprise, in addition or alternatively, information about at least one thermal property of the unprocessed food or food product ready to be cooked. If applicable, at least one thermal property of the food product ready to be cooked, in particular its density, thermal conductivity and/or heat capacity, is estimated on the basis of the cooking recipe information and the basic nutrient information. At least one cooking parameter of the cooking process, in particular temperature of the cooking equipment and/or environment, duration of a cooking program and/or program segment and/or program step, heating mode, etc., is defined based on the food model (30) and/or on at least the provided or estimated at least one thermal property of the food product.
Worldwide, the burden of chronic kidney disease (CKD) has increased rapidly and is a lethal disease. The klotho protein plays a vital role in the regulatory mechanism in the progression of CKD. Particularly the decreased expression of klothoand its genetic variations might affect the potency of drugs. This study aims to identify a new drug molecule, which works equipotential in all types of klotholike wild and mutant variants. All non-synonymous SNPs were predicted by several SNP tools. Where, two missense variants were examined as vulnerable, significantly damaging, and also involved in the structural conformational changes of the protein. Based on structure-based screening, E-pharmacophore screening, binding mode analysis, binding free energy analysis, QM/MM, and molecular dynamics analysis a lead compound (Lifechemical_F2493-2038) was identified as an effective agonistic molecule hence the identified Lifechemical_F2493-2038 compound is well bound to the wild and mutant proteins which found to increase the expression of klotho.Communicated by Ramaswamy H. Sarma.
The present invention relates to a formula for preparing Sanlu tonic wine for warming the kidney and a technology thereof. The ingredients of the tonic wine adopt pilose antler, antler blood and penis cervi of a spotted deer in northeast and gecko as main medicines which are matched with various rare traditional Chinese medicines, such as astragalus root, codonopsis pilosula, lignum millettiae, etc. to be refined into the tonic wine by a special method. The tonic wine comprises various amino acids and trace elements essential to a human body and are rich in nutrient components, such as vitamin, cephalin, folic acid, etc. The tonic wine has the functions of central nervous excitement, immunity enhancement for the human body, fatigue resistance, senescence resistance, memory increase, etc.; furthermore, the tonic wine has the favorable effect on symptoms, such as impotence, nocturnal emission, waist and knee ache, dysthesia, amnesia, deficient cold of the spleen and the stomach, etc.; particularly, the tonic wine has the specific effect on hypogonadism, impotence and prospermia.
BACKGROUND: Surgical site infection (SSI) is a significant concern due to its potential to cause delayed wound healing and prolonged hospital stays. This study aims to develop a predictive model in patients with Crohn's disease.
METHODS: We conducted single-factor and multi-factor logistic regression analyses to identify risk factors, resulting in the development of a logistic regression model and the creation of a nomogram. The model's effect was validated by employing enhanced bootstrap resampling techniques, calibration curves, and DCA curves. Finally, we investigated the risk factors for wall and intra-abdominal infections separately.
RESULTS: 90 of 675 patients (13.3 %) developed SSI. Several independent risk factors for SSI were identified, including higher postoperative day one neutrophil count (p = 0.033), higher relative blood loss (p = 0.018), female gender (p = 0.021), preoperative corticosteroid use (p = 0.007), Montreal classification A1 and L2 (p < 0.05), previous intestinal resection (p = 0.017), and remaining lesions (p = 0.015). Additionally, undergoing strictureplasty (p = 0.041) is a protective factor against SSI. These nine variables were used to develop an SSI prediction model presented as a nomogram. The model demonstrated strong discrimination (adjusted C-statistic=0.709, 95 % CI: 0.659∼0.757) and precise calibration. The decision curve showed that the nomogram was clinically effective within a probability threshold range of 3 % to 54 %. Further subgroup analysis revealed distinct risk factors for wall infections and intra-abdominal infections.
CONCLUSION: We established a new predictive model, which can guide the prevention and postoperative care of SSI after Crohn's disease bowel resection surgery to minimize its occurrence rate.
AIM: Cardiometabolic conditions such as cardiovascular disease, type 2 diabetes, and chronic kidney disease contribute to multimorbidity, posing a global health challenge. However, existing healthcare frameworks often struggle to adequately address the intricate needs of individuals living with these conditions. The review aims to map existing research on cardiometabolic care initiatives for the primary and secondary prevention of metabolic conditions.
DATA SYNTHESIS: A scoping review was conducted following the methodology of the Joanna-Briggs-Institute. We searched Medline, Embase, and CINAHL. The review primarily sought studies comparing the effectiveness of cardiometabolic services/clinics in primary or secondary prevention of cardiometabolic conditions with standard care. The data from these studies were charted and summarised in tabular form, with a narrative synthesis. The search identified 97 records across three databases, and 18 documents met inclusion criteria. Two studies addressed cardiometabolic care in primary prevention, while twelve focused on secondary prevention. Positive outcomes were observed in primary prevention, including reductions in waist circumference, body mass index, blood pressure, and cholesterol levels. For secondary prevention, the studies demonstrated positive metabolic outcomes, such as reductions in HbA1c, weight, blood pressure, and cholesterol levels. Additionally, data from the available studies reported improved adherence to diabetes care processes and the implementation of guideline-directed therapies.
CONCLUSION: This scoping review highlights the potential benefits of services such as cardiometabolic clinics for primary and secondary prevention in metabolic conditions. Future studies should use standardised outcome measures and include details on the structure, staffing and treatment intensity of clinics to aid their wider implementation.
PROBLEM TO BE SOLVED: To obtain the subject food capable of preventing the decalcification of dental enamel and reinforced in an action for preventing dental carries by adding a specific antiacid to a pasty food for tooth pastes. SOLUTION: This pasty food for tooth pastes is obtained by adding one or plural kinds of antiacids selected from sodium bicarbonate, precipitated calcium carbonate and magnesium metasilicate aluminate to starch paste. The pasty food is obtained e.g. by a method comprising putting starch (e.g. cross- linked starch), an antiacid, water and, if necessary, one or more kinds of saccharides selected from maltitol, sorbitol, xylitol, palatinose, fructooligo saccharide, galactooligo saccharide and the like in a pan, heating the mixture preferably at a temperature of about 90 deg.C with stirring, sprinkling a peppermint solution on the starch product and subsequently stirring the mixture. The food has physical properties such as rapid water separability, shape retainability and refreshing taste retainability.
BACKGROUNDS: Long nonconding RNAs (lncRNAs) have been found to be a vital regulatory factor in the development process of human cancer, and could regarded as diagnostic or prognostic biomarkers for human cancers. Here, we aim to confirm the expression and molecular mechanism of RP11-171K16.5 (lnc171) in hepatocellular carcinoma (HCC).
METHODS: Screening of differentially expressed lncRNAs by RNA sequencing. Expression level of gene was studied by quantitative real-time PCR (qRT-PCR). The effects of lnc171, mir-873-5p, and ethanol on migration and invasion activity of cells were studied used transwell assay, and luciferase reporter assay was used to confirm the binding site.
RESULTS: RNA sequencing showed that lnc171 was markedly up-regulated in HCC. siRNA-mediated knockdown of lnc171 repressed the migration and invasion ability of HCC cells. Bioinformatic analysis, dual luciferase reporter assay, and qRT-PCR indicated that lnc171 interacted with mir-873-5p in HCC cells, and Zin-finger E-box binding homeobox (ZEB1) was a downstream target gene of mir-873-5p. In addition, lnc171 could enhance migration and invasion ability of HCC cells by up-regulating ZEB1 via sponging mir-873-5p. More interestingly, ethanol stimulation could up-regulate the increase of lnc171, thereby regulating the expression of competing endogenous RNA (ceRNA) network factors which lnc171 participated in HCC cells.
CONCLUSIONS: Our date demonstrates that lnc171 was a responsive factor of ethanol, and plays a vital role in development of HCC via binding of mir-873-5p.
The present invention relates to an antioxidant composition containing an extract of Malus prunifolia Wild. Borkh as an effective component, and more specifically, to an antioxidant composition which contains an extract of Malus prunifolia Wild. Borkh of Adams varieties, which are ripe varieties of Malus prunifolia Wild. Borkh, as an effective component and has potent DPPH anion scavenging activity, ABTS cation scavenging activity, nitrite scavenging activity, and reducing ability, wherein the antioxidant composition is for use in a pharmaceutical composition, a health functional food, or a functional cosmetic composition. The extract of Malus prunifolia Wild. Borkh of Adams varieties as an effective component of the antioxidant composition of the present invention, as demonstrated in embodiments in the present specification, exhibits extremely potent scavenging activity with respect to active anions, active cations, and nitrite, and at the same time, exhibits excellent reducing ability. The effective component may be processed in various forms such as extract, powder, pills, tablets and the like and applied for use in pharmaceutical compositions, health functional food, or functional cosmetic compositions, and the like, and hence is an extremely useful invention.
The purpose of the study is to determine if the administration of liposomal bupivacaine at the completion of a suburethral sling procedure will result in decreased postoperative pain compared to no injection. The hypothesis is that administration of liposomal bupivacaine at the completion of retropubic suburethral sling procedure will result in decreased postoperative pain compared to no injection. Although multiple routes for sling placement exist, no difference in pain has been found when comparing obturator verses retropubic suburethral sling. Previous trials have investigated varying formulations of injections along the sling pathway in order to reduce complications such as pain and voiding dysfunction. Local anesthesia along the trocar pathway has shown some improvements in pain. Other techniques, however, have varying results. In 2011, the FDA approved liposomal bupivacaine as a single dose wound infiltration for treatment of postoperative pain following hemorrhoidectomy and bunionectomy. Initial studies demonstrated decreased pain compared to placebo, prolonged release in a bimodal distribution, and greater sensory than motor blockade. Additionally, postoperative benefits such as decreased overall pain, decreased opioid use, and increased time to opioid need were observed. Liposomal bupivacaine may also have the advantage of reducing hospital stays and decreasing overall hospital costs. The side effect profile has similar or improved rates of adverse events compared to traditional bupivacaine, a favorable cardiac profile, and no increased risk of poor wound healing. With such promise, we aim to evaluate the use of liposomal bupivacaine to reduce postoperative pain for the placement of slings to treat stress urinary incontinence. The study will be a blinded randomized controlled trial. Patients randomized to receive liposomal bupivicaine, the standard 20ml vial will be diluted with 1 Oml of saline to a reconstituted volume of 30 ml. Those in the control group will receive 30ml of normal saline injected in the same fashion as the study arm.
Participants in the Control group will receive psycho-educational support via monthly sessions led by researchers with experience in child development. In each session, a presentation will be delivered to provide parents with information about child development and environmental factors that contribute to healthy child development, including sensitive parenting styles, frequent positive social interactions between parents and children and cognitive stimulation. The presentations will be followed by group discussions. Children will also continue to receive Community Assistance as Usual via their normal early education centers. These centers offer daily activities designed to promote children's learning, autonomy, movement, integration and socialization. Children attend their educational center five days per week between the hours of 8am and 5pm.
PROBLEM TO BE SOLVED: To provide methods for treating a patient with a cardiac or vascular disease, disorder, symptom, or failure that is peripheral vascular disease, acute or chronic myocardial infarction, cardiomyopathy, congestive or chronic heart failure, cardiovascular ischemia, hypertensive pulmonary vascular disease, peripheral arterial disease, or rheumatic heart disease.SOLUTION: An angiogenic method from a population of placental perfusate cells comprises contacting a cell population to an angiogenesis promoting condition. The population of placental perfusate cells is that of total nucleated cells derived from a placental perfusate. The contacting comprises contacting the cells to VEGF (50 to 200 ng/mL), TGF-β (1 to 5 ng/mL), FGF (10 to 50 ng/mL) and one or more matrix metalloprotease (each 1 to 3 Unit/mL). The contacting is performed in vitro or in vivo. The population of placental perfusate cells comprises the placental perfusate cells isolated from the perfusion of a single placenta. The placental perfusate cells are CD34+ cells.SELECTED DRAWING: None